Ermont

Karyopharm Therapeutics is an innovation-driven pharmaceutical company based in Newton Center, MA. They are dedicated to the discovery, development, and commercialization of medicines aimed at improving the lives of patients with cancer and other major diseases. With a focus on oral Selective Inhibitor of Nuclear Export (SINE) technology, Karyopharm is a leader in addressing the fundamental mechanism of oncogenesis, the process through which healthy cells transform into cancer cells. They have a robust pipeline of four unique drug candidates in clinical development, targeting patients with cancer in both hematologic and solid tumors. At Karyopharm, patients are at the core of their mission. They are committed to developing important new medicines that can make a difference in patients' lives. With ongoing clinical trials for their lead drug candidate and next-generation programs, Karyopharm is actively exploring treatments in earlier lines of treatment, combination trials, and various tumor types across both hematologic and solid tumors. Their dedication to patients and innovative approach to drug development sets them apart in the pharmaceutical industry.Generated from the website